Vaccines
H1N1
Video clips / soundbites
Andrin Oswald, CEO of Novartis Vaccines and Diagnostics — at the Marburg, Germany cell culture vaccine manufacturing facility — discusses the need for ongoing pandemic preparedness.
Images
Celtura
Celtura labeling
Single-dose, pre-filled syringes of Celtura, a Novartis cell culture-based Influenza A(H1N1) vaccine (pre-labeling)
Celtura labeling
Single-dose, pre-filled syringes of Celtura, a Novartis cell culture-based Influenza A(H1N1) vaccine (post-labeling).
Celtura
Pack shot of Celtura®, a Novartis cell culture-based Influenza A(H1N1) vaccine (single-dose, pre-filled syringes)
Fluvirin
Fluvirin multidose viral
Pack shot of Fluvirin, a Novartis egg-based Influenza A (H1N1) vaccine (multi-dose vial)
Fluvirin syringe
Single-dose, pre-filled syringe of Fluvirin, a Novartis egg-based Influenza A (H1N1) vaccine
Fluvirin
Fluvirin, a Novartis egg-based Influenza A(H1N1) vaccine (pre-labeling)
Focetria
Focetria carton syringes
Pack shot of Focetria H1N1 vaccine (pre-filled syringes).
General
Inspection
Inspection of a syringe containing H1N1 vaccine during filling process. The white color is due to the addition of the adjuvant MF59.
You may use the multimedia material provided in this section for commercial purposes only in relation to Novartis. These images must not be modified in any way and each item must have the copyright acknowledgement of Novartis AG (© Novartis AG).
About Novartis
We provide medicines to treat and prevent diseases, ease suffering and improve quality of life.
Research
Novartis is working to build the most promising pipeline in the industry to treat and help people around the world.